Chronogen, Inc. Company Profile

With an aging population, the prevalence of age-related diseases is expected to mount rapidly over the next decade and new drugs are needed. Cardiovascular and metabolic diseases, cancer, neurodegenerative diseases represent huge markets that Biotech and Pharma companies are targeting.
Initially, Chronogen has focused all activities on the identification and the characterization of longevity target genes, cloned by means of long-lived mutants of the nematode C. elegans. For those genes that were also found to be expressed in human cells, Chronogen has developed a series of proprietary technologies and screening assays aimed at the identification of small molecule modulators mimicking the genetic effects obtained in C. elegans mutants, or equivalent mouse models. Efforts are now focused on the development of drug candidates, selected through unique screening assays, which modulate the production of molecules responsible for cardiovascular, metabolic and central nervous system diseases: Reactive Oxygen Species (ROS) in oxidative stress and Low density Lipoprotein (LDL) in dyslipidemia. Headquartered in Montreal, Canada, Chronogen now employs over 25 scientists.

Location

2901 Rachel E. Suite 22
Montreal
Quebec
H1W 4A4
Canada

More Information about "Chronogen, Inc." on BioPortfolio

We have published hundreds of Chronogen, Inc. news stories on BioPortfolio along with dozens of Chronogen, Inc. Clinical Trials and PubMed Articles about Chronogen, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chronogen, Inc. Companies in our database. You can also find out about relevant Chronogen, Inc. Drugs and Medications on this site too.